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Risk factors for upper gastrointestinal bleeding among end-
stage renal disease patients.
Background. The risk of upper gastrointestinal bleeding
(UGIB) is increased among end-stage renal disease (ESRD)
patients compared to the general population. However, corre-
lates of UGIB among ESRD patients remain unknown. We
conducted a cohort study of dialysis patients to ascertain risk
factors for UGIB.
Methods. Data from the United States Renal Data System
Dialysis Morbidity and Mortality Studies, Waves 2–4 were
used to identify risk factors for incident UGIB among ESRD
patients. First hospitalizations for UGIB were identified using
hospital diagnosis codes between 12/31/93 and 12/31/99. Cox
regression was used to estimate the association between pre-
dictors of interest and first diagnosis of UGIB.
Results. Cases of UGIB (698) were observed over 30,648
patient years of follow-up. Before adjustment for confounding
factors, increasing age, diabetes, former and current smoking,
cardiovascular disease (CVD), lower serum albumin, malnutri-
tion, and inability to ambulate independently were associated
with an increased risk of UGIB, while African Americans and
transplant patients had a lower risk of UGIB. After adjustment,
African American race was associated with a lower risk of
UGIB (RR  0.90; 0.82, 0.98), while current smoking (RR 
1.11; confidence interval 1.03, 1.19), history of CVD (RR 
1.32; 1.10, 1.59), and inability to ambulate independently
(RR  1.32; 1.07, 1.63) were associated with a higher risk of
UGIB. Age, gender, diabetes, lower serum albumin, nourish-
ment, treatment modality, aspirin use, nonsteroidal anti-inflam-
matory drug (NSAID) use, and antiplatelet or anticoagulant
medication use were not found to be significantly related to
the risk of UGIB after adjustment for potential confounding
factors.
Conclusion. CVD, current smoking, and risk factors sug-
gesting more disability are associated with a greater risk of
UGIB among patients with ESRD.
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Each year in the United States there are approximately
100 hospitalizations for upper gastrointestinal bleeding
(UGIB) per 100,000 adults [1]. Furthermore, the occur-
rence of UGIB has been associated with a mortality rate
of 5 to 15% [1–3]. The estimated annual cost of these hos-
pitalizations exceeds $2.5 billion [4]. Reports suggest that
the risk of UGIB may be greater among patients with
acute renal failure, and among those with a serum creati-
nine 2.5 mg/dL [5–9]. Among end-stage renal disease
(ESRD) patients, it has been estimated that UGIB ac-
counts for 3 to 7% of all deaths [5]. The reasons for the
high incidence of UGIB among those with ESRD are
not known. In particular, it is not known what role factors
known to increase the risk for UGIB in the general
population may play in the dialysis population, including
age, gender, alcohol use, smoking, ulcer disease, cardio-
vascular disease, immobilization, and anti-inflammatory
medicine [6, 9–17]. Furthermore, it is not know if dialysis-
specific factors such as heparin exposure during hemodi-
alysis and platelet dysfunction resulting from uremia may
also increase the risk of UGIB. We utilized data from
the United States Renal Data System (USRDS) Dialysis
Morbidity and Mortality Studies, Waves 2–4 (USRDS
DMMS, 2–4) to ascertain risk factors for UGIB among
the ESRD patients.
METHODS
Subjects
Data for this study were obtained from the USRDS,
a database containing demographic and clinical informa-
tion on all United States ESRD patients surviving more
than 90 days on renal replacement therapy and who
qualify for Medicare. For the purposes of this study, we
used data from the USRDS DMMS 2–4. Briefly, DMMS
Wave 2 was a prospective study in which data were
collected on a random sample of 4024 incident hemodial-
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ysis and peritoneal dialysis patients initiating therapy in
December of 1996. DMMS Waves 3 and 4 were historic
prospective studies in which data were collected on a
random sample of 11,142 prevalent ESRD patients re-
ceiving in-center hemodialysis on December 31, 1993.
Although these special studies were conducted at differ-
ent times and locations, data collection procedures and
content were kept consistent across the studies, allowing
them to be combined for analysis. Greater detail of the
USRDS and these special studies is described else-
where [18].
All ESRD patients with a valid USRDS identification
number who participated in DMMS Wave 2, 3, or 4,
survived more than 90 days on renal replacement ther-
apy, and had treatment history records available, were
considered eligible for the current study. In addition,
only patients for whom Medicare was the primary payer
of medical expenses at study start (81% of participants in
DMMS Waves 2–4) were considered eligible for analysis.
Since the current study sought to identify factors which
may be associated with incident UGIB after initiation
of dialysis, those patients who were reported as having
experienced an UGIB between the date of initiation of
care for ESRD and study start were excluded. In total,
10,842 patients met the inclusion criteria for the study
(2479 from Wave 2; 4332 from Wave 3; and 4031 from
Wave 4).
Risk factor identification
Covariates identified a priori as possible risk factors
for UGIB were abstracted from the USRDS patient de-
mographics file, the USRDS treatment history file, and
the DMMS Waves 2–4 data files. Variables of interest
included age at study start, gender, race (black, white,
other), diabetes, treatment modality (hemodialysis, peri-
toneal dialysis, transplant), smoking status (never, for-
mer, current), cardiovascular disease (CVD), subjective
assessment of undernourishment (yes, no), ability to am-
bulate independently (yes, no), KT/V, serum albumin,
aspirin use (yes, no), non-steroidal medication use (yes,
no), antiplatelet medication use (yes, no), and H2 blocker
or proton pump inhibitor use (yes, no).
Outcome definition
Medicare billing data from December 31, 1993 to De-
cember 31, 1999 were linked to DMMS Wave 2–4 data
via unique patient identification numbers. Patients were
considered to have experienced a UGIB if a primary
hospital discharge diagnosis indicating UGIB, as defined
by any one of the International Classification of Diseases,
9th Revision (ICD9) diagnosis codes consistent with
esophageal, gastric, duodenal, peptic, and gastrojejunal
Table 1. ICD-9 codes for upper GI bleeds
ICD-9 code Description
530.4, 530.7, 530.82 Esophageal
578.0 Hematemesis
531.00, 531.10, 531.20, 531.40,
531.50, 531.60, 531.80 Gastric ulcer
532.00, 532.10, 532.20, 532.40,
532.50, 532.60, 532.80 Duodenal ulcer
533.00, 533.10, 533.20, 533.40,
533.50, 533.60, 533.80 Peptic ulcer
534.00, 534.10, 534.20, 534.40,
534.50, 534.60, 534.80 Gastrojejunal ulcer
535.X1 Gastritis/duodenitis with bleeding
bleeds were reported (Table 1). Gastrointestinal bleed,
unspecified, was not used to identify UGIB because it
was felt to be too nonspecific with regard to location of
bleeding. Primary billing codes, rather than secondary
codes, were used to better capture hospitalizations for
which UGIB was the primary reason for hospitalization.
Secondary billing codes were felt more likely to reflect
UGIBs that occurred after hospitalization.
Statistical analysis
Patient characteristics were summarized by the mean
and corresponding standard deviation for continuous co-
variates and frequency for categorical covariates. In the
event that Medicare billing data were not received over
a continuous period of one year, patients were consid-
ered lost to follow-up. For all analyses, patients were
considered at risk for UGIB from the maximum of
90 days following initiation of care for renal replacement
therapy and the date of study start for their respective
special study to the minimum date of UGIB, death, loss
to follow-up, loss of Medicare coverage, or 12/31/1999.
UGIB event rates were computed by dividing the total
number of first primary diagnoses of UGIB by the total
number of patient-years at risk.
To model the time from study start to the first report
of UGIB, proportional hazards regression for censored
survival data was used. Covariates were adjusted for mul-
tivariate models if a priori they were considered to be
associated with the risk of UGIB. H2-blocking medica-
tions were not included in the multivariate analysis be-
cause of the potential for confounding by indication.
Given the availability of data indicating ESRD treatment
history over the course of the current study, treatment
modality was modeled as a time-dependent variable, im-
plying that patients were able to switch risk groups over
the course of follow-up. All continuous variables consid-
ered for adjustment in the analysis were hypothesized to
be linearly related to the outcome of interest, and forced
into the model assuming this functional form. However,
in secondary analyses, continuous variables were also
categorized and diagnostic plots were used to verify that
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the assumption of linearity was a reasonable one. Regres-
sion models were stratified by study participation (Waves
2, 3, and 4), implying that the association between each
covariate of interest and the risk of UGIB was estimated
within each special study, and estimates were then com-
bined across the three strata. Point estimates associated
with each covariate of interest did not differ appreciably
across strata. Graphical diagnostics as well as formal
hypothesis tests were used to determine the appropriate-
ness of the assumption of proportional hazards for each
adjustment covariate. All analyses were performed on a
complete-case basis.
RESULTS
Cases of UGIB (698) were observed over 30,648 pa-
tient years of follow-up. Follow-up time on patients
ranged between 1 day and 6 years, with a median of 2.7
years. Table 2 presents selected characteristics of the
patients included in our analysis and the corresponding
incidence densities for UGIB. At the time of study en-
rollment, the mean patient age was 61.0 years. Fifty-one
percent of the patients in the current study were male,
and 55% were Caucasian. Patients were more likely to
be non-diabetic at the initiation of care for ESRD and
non-smokers. The incidence of UGIB, regardless of
study period, exceeded 21 bleeds per 1000 persons per
year, and was highest among Caucasians, diabetics, cur-
rent smokers, those with a history of CVD, those unable
to ambulate independently, and those identified as un-
dernourished. Figure 1 depicts incidence densities for
those sources of bleeding considered in the study. Gastric
ulcers were found to be the most common source of
bleeding (7.0 per 1000 persons per year), while bleeding
resulting from a gastrojejunal ulcer was least frequent
(0.1 per 1000 persons per year). Duration of hospital
stays for those patients diagnosed with a UGIB ranged
between 1 and 87 days, with a median hospital stay of
5 days. For those hospital admissions resulting in a diag-
nosis of an UGIB, 73.2% of the surgical procedures
performed during the hospital stay pertained to hemodi-
alysis (ICD-9 surgical code 39.95; 12.6%), endoscopy
(ICD-9 surgical codes 44.43, 45.13, and 45.16; 58.3%),
and transfusion (ICD-9 surgical code 99.04; 2.3%).
Table 3 presents estimates of the unadjusted and ad-
justed relative risk for UGIB associated with each covari-
ate of interest. Prior to adjustment, the incidence of
UGIB was estimated to increase by 11% with each in-
creasing decade of life [95% confidence interval (CI),
1.05 to 1.16, P  0.001), and African Americans were
estimated to experience a 12% lower risk of UGIB when
compared to Caucasians (95% CI, 0.82 to 0.96, P 
0.002). The risk of UGIB did not differ significantly by
gender. Diabetics were estimated to have a 13% higher
risk of UGIB when compared to those without diabetes
(95% CI, 1.05 to 1.22, P  0.001), while former and
current smokers had an 11% (95% CI, 1.01 to 1.21, P 
0.027) and 7% (95% CI, 1.00 to 1.15, P  0.036) greater
risk of UGIB, respectively. Patients with a history of
CVD were estimated to experience a 1.6-fold increase
in the risk of UGIB when compared to those without
CVD (95% CI, 1.33 to 1.80, P  0.001). Each 1 mg/dL
decrease in albumin was associated with a 36% increased
risk of UGIB (95% CI, 1.12 to 1.63, P  0.001). Those
patients who were subjectively considered undernour-
ished or unable to ambulate independently experienced
a 48% (95% CI, 1.19 to 1.84, P  0.001), and 57% (95%
CI, 1.32 to 1.87, P  0.001) increased risk of UGIB re-
spectively, when compared to patients without these fac-
tors. Renal transplant recipients experienced a 17%
lower risk of UGIB when compared to patients treated
with chronic hemodialysis (95% CI, 0.71 to 0.96, P 
0.014). In bivariate analyses, the use of antiplatelet or
anticoagulant medications was not found to be signifi-
cantly associated with the risk of UGIB. Kt/V was also
not found to be associated with an increased risk of
UGIB.
Following adjustment for potentially confounding fac-
tors, African Americans were estimated to have a 10%
lower risk of UGIB when compared to Caucasians (95%
CI, 0.82 to 0.98; P  0.021) and current smokers were
estimated to have experienced an 11% increase in the
risk of UGIB compared to those who had never smoked
(95% CI, 1.03 to 1.19, P 0.008). Patients with CVD had
a 32% higher risk of an UGIB (95% CI, 1.10 to 1.59,
P  0.003) when compared to those without. The risk
of UGIB was estimated to increase by 32% for patients
reportedly unable to ambulate independently (95% CI,
1.07 to 1.63, P  0.010). Following adjustment for con-
founders, peritoneal dialysis and transplantation (rela-
tive to hemodialysis) were not significantly associated
with the risk of UGIB. Other factors that were no longer
statistically significant correlates of UGIB after adjust-
ment included diabetes, malnourishment, serum albu-
min, and antiplatelet and anticoagulant medication use.
DISCUSSION
We conducted a cohort study to determine risk factors
for incident UGIB among ESRD patients. The incidence
of UGIB, regardless of study period, was greater than
21 bleeds per 1000 persons per year. In bivariate analyses,
age, African American race, diabetes, former and current
cigarette smoking, a history of CVD, lower serum albu-
min, undernourishment, and inability to ambulate inde-
pendently were all associated with the risk of UGIB.
Renal transplant recipients and peritoneal dialysis pa-
tients had a lower risk of UGIB compared to hemodialy-
sis patients prior to adjustment for potential confounding
factors. Following adjustment, African American race
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Table 2. Patient characteristics
Mean (SD) or Number of Incidence density
Characteristic N (%) Person years upper GI bleeds (per 1000 per year)
DMMS Wave
Wave 2 2479 (22.9%) 5307 124 23.4
Wave 3 4332 (40.0%) 13,033 278 21.3
Wave 4 4031 (37.2%) 12,308 296 24.0
Age at study start years 61.01 (15.61) 30,648 698 22.8
Gender
Male 5576 (51.4%) 15,817 367 23.2
Female 5266 (48.6%) 14,831 331 22.3
Race
White 5976 (55.2%) 15,180 390 25.7
Black 4308 (39.8%) 13,771 273 19.8
Other 550 (5.1%) 1670 34 20.4
Diabetes as primary cause of
ESRD
No 5649 (55.7%) 17,612 364 20.7
Yes 4490 (44.3%) 11,206 301 26.9
Smoking status
Never 4930 (52.9%) 14,779 302 20.4
Former 2928 (31.4%) 7656 193 25.2
Current 1463 (15.7%) 4300 120 27.9
History of CVD
No 5096 (47%) 16,680 300 18.0
Yes 5746 (53%) 13,969 398 28.5
Serum albumin g/dL 3.67 (0.45) 30,648 698 22.8
Undernourished
No 8257 (84%) 25,068 542 21.6
Yes 1568 (16%) 2939 96 32.7
Ability to ambulate
No 2766 (27.3%) 5751 187 32.5
Yes 7362 (72.7%) 23,111 473 20.5
Aspirin use
No 9315 (85.9%) 26,630 601 22.6
Yes 1527 (14.1%) 4019 97 24.1
NSAIDs use
No 10,314 (95.1%) 29,153 657 22.5
Yes 528 (4.9%) 1495 41 27.4
Antiplatelet use
No 10,562 (97.4%) 29,916 686 22.9
Yes 280 (2.6%) 732 12 16.4
H2 antogonists use
No 8328 (76.8%) 24,053 529 22.0
Yes 2514 (23.2%) 6595 169 25.6
Proton pump inhibitors use
No 8729 (80.5%) 25,088 544 21.7
Yes 2113 (19.5%) 5560 154 27.7
Other medication usea
No 10,138 (93.5%) 28,890 660 22.8
Yes 704 (6.5%) 1758 38 21.6
a Includes warfarin, lepirudin, heparin, argatroban, aprotinin, enoxaparin, dalteparin, danaparoid, and lovenox
was associated with a decrease in the risk of UGIB,
while current smoking, history of CVD, and inability to
ambulate were all associated with an increased risk of
UGIB. Factors not associated with UGIB in the adjusted
analysis included age, gender, diabetes, Kt/V, treatment
modality, aspirin, NSAIDs, and antiplatelet or anticoag-
ulation medication use.
Our findings are comparable to those described among
the general population, which report that CVD, current
smoking, and co-morbidities such as inability to ambu-
late, place individuals at a greater risk of UGIB [6, 9,
19–21]. Kaplan et al [6] reported a 42% higher risk of
UGIB associated with age 70, an almost 2-fold greater
risk of UGIB associated with CVD, and a 2-fold
greater risk associated with current smoking in the gen-
eral population. Pahor et al [19, 20] describe several
possible mechanisms for the increased risk of UGIB
among inactive, elderly patients with CVD, including gut
ischemia and reduced splanchnic circulation, which are
both thought to worsen with inactivity. These vascular
lesions may be particularly problematic among ESRD
patients, who have pre-existing vascular disease, diabe-
tes, and uremic factors, which accelerate microvascular
pathology. In addition, several reports from the general
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Table 3. Stratifieda Cox regression estimates modeling the time to first upper GI bleed
Unadjusted Adjustedb
Relative risk Relative risk
Covariate (95% CI) P value (95% CI) P value
Age (per decade) 1.11 (1.05, 1.16) 0.001 1.03 (0.97, 1.10) 0.290
Gender (female vs. male) 0.96 (0.83, 1.11) 0.578 0.96 (0.80, 1.14) 0.631
Race
White 1.0
Black 0.88 (0.82, 0.96) 0.002 0.90 (0.82, 0.98) 0.021
Other 0.97 (0.86, 1.09) 0.607 0.98 (0.86, 1.12) 0.753
Diabetes (yes vs. no) 1.13 (1.05, 1.22) 0.002 1.06 (0.97, 1.17) 0.179
Smoking status
Never 1.0
Former 1.11 (1.01, 1.21) 0.027 1.07 (0.97, 1.19) 0.158
Current 1.07 (1.00, 1.15) 0.036 1.11 (1.03, 1.19) 0.008
History of CVD (yes vs. no) 1.55 (1.33, 1.80) 0.001 1.32 (1.10, 1.59) 0.003
Serum albumin (per 1 mg/dL decrease) 1.36 (1.12, 1.63) 0.001 1.18 (0.95, 1.46) 0.141
Undernourished (yes vs. no) 1.48 (1.19, 1.84) 0.001 1.23 (0.96, 1.59) 0.105
Ability to ambulate (no vs. yes) 1.57 (1.32, 1.87) 0.001 1.32 (1.07, 1.63) 0.010
Treatment modality
HD 1.0
PD 0.88 (0.75, 1.04) 0.132 0.88 (0.72, 1.07) 0.205
Transplant 0.83 (0.71, 0.96) 0.014 0.94 (0.80, 1.11) 0.485
Aspirin use (yes vs. no) 1.06 (0.85, 1.31) 0.612 0.95 (0.74, 1.21) 0.684
NSAIDs use (yes vs. no) 1.22 (0.89, 1.67) 0.220 1.20 (0.84, 1.71) 0.319
Antiplatelet use (yes vs. no) 0.72 (0.41, 1.27) 0.254 0.81 (0.45, 1.43) 0.461
Other medication use (yes vs. no) 0.94 (0.68, 1.30) 0.693 0.95 (0.67, 1.35) 0.794
Abbreviations are: CVD, cardiovascular disease; DMMS, Dialysis Morbidity and Mortality Studies; GI, gastrointestinal; HD, hemodialysis; NSAIDs, non-steroidal
anti-inflammatory drugs; PD, peritoneal dialysis.
a Model is stratified by DMMS study participation
b Adjusted for all covariates listed
Fig. 1. Estimated incidence densities (per 1000 per year) for those
categories of upper gastrointestinal bleeding (UGIB) displayed in Table
1. Incidence densities were calculated by dividing the total number of
diagnoses occurring in the study sample by the total person years at
risk and multiplying by 1000.
population cite an association between cigarette smoking
and UGIB. Anderson et al [22] reported a strong associa-
tion between current tobacco use and hospitalization for
a perforated peptic ulcer (RR  3.5, 95% CI, 1.7 to
7.1). In addition, Kaplan et al [6] reported that smokers
greater than 65 years old had a higher risk of hospitaliza-
tion for UGIB compared to non-smokers (HR  2.14,
95% CI, 1.22 to 3.75). Although the exact mechanism
has not been determined, it is proposed that smoking
inhibits prostaglandins in the upper gastrointestinal tract,
causing mucosal vasoconstriction and possible ischemia
[22–24]. This effect may be especially pronounced among
patients with ESRD who smoke and have microvascular
disease, placing them at greater risk of UGIB compared
to the general population.
Unlike many reports from the general population, we
did not find an association between UGIB and use of as-
pirin, non-steroidal medications, or anticoagulants [1, 15,
25–29]. In our study, it is possible that medications such
as aspirin or non-steroidals were under-reported, since
these are non-prescription medications. In addition, medi-
cation use in our study was ascertained at only one time
point, potentially leading to misclassification. Finally, pa-
tients at greatest risk of UGIB may avoid particular
medications that could increase the risk of UGIB, such
as anticoagulants or non-steroidals, or may be placed on
prophylactic medications such as proton-pump inhibi-
tors, thereby decreasing the risk of a UGIB.
Several dialysis specific factors have been postulated
to increase the risk of UGIB, including poor platelet
function resulting from uremia, mucosal abnormalities of
the gastrointestinal tract, and hypergastrinemia [5, 30–32].
We were unable to find an association between Kt/V, a
possible surrogate marker for uremia, and risk of UGIB.
Wasse et al: Risk factors for upper gastrointestinal bleeding1460
However, Kt/V may not accurately reflect uremic factors
that are important in the pathogenesis of UGIB among
ESRD patients. Alternatively, our study may not have
been able to detect such an association, since Kt/V was as-
sessed at a single time point. This may have led to non-
differential misclassification, underestimating the associ-
ation of Kt/V with UGIB. It has also been hypothesized
that intermittent anticoagulation may place hemodialysis
patients at greater risk for UGIB. If this were the case,
one would anticipate that peritoneal dialysis and renal
transplantation would be associated with a lower risk
for UGIB compared to hemodialysis. In bivariate analy-
ses, we found a lower risk of UGIB associated with renal
transplant. However, following adjustment for potential
confounding factors, the association between treatment
modality and UGIB was no longer found to be statisti-
cally significant, although point estimates indicated that
patients receiving peritoneal dialysis, or those with a
renal transplant may be at a lower risk of UGIB when
compared to hemodialysis patients. It is possible that
factors such as chronic prednisone use and infection pre-
dispose these patients to peptic ulcer disease and increase
the risk of UGIB [33–35].
Our study has several limitations. First, we have identi-
fied patients with UGIBs based on ICD-9 coding, which
may result in some misclassification. However, this mis-
classification should be non-differential and result in an
attenuation of estimated effects and less power to detect
differences between groups. Second, we lack longitudi-
nal information regarding medications, and nonprescrip-
tion medications may be under-reported. Finally, we lack
information regarding the presence of Helicobacter pylori
among these patients, and are unable to assess this as a
risk factor. Future prospective studies may be able to bet-
ter estimate the association between medication use and
UGIB. Despite these limitations, this study combines
data on over 10,000 ESRD patients from around the
country, and therefore the results should be generaliz-
able to the entire ESRD population and not reflect spe-
cific dialysis unit practices.
CONCLUSION
Current cigarette smoking, the presence of CVD, and
risk factors suggesting more disability are associated with
a greater risk of UGIB among patients with ESRD.
Further studies need to assess whether smoking cessation
and the use of H2 blockers and proton pump inhibitors
may reduce the risk of UGIB in these high-risk patients.
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